Xanthohumol as an Adjuvant in the Treatment of Septic Shock

Recruiting Phase 2 Interventional Study
Septic Shock Pneumonia ARDS
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
Medical University of Lublin · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Septic shock (SS) is a life-threatening condition resulting from excessive inflammatory response to bacterial, viral or/and fungal infections. It is associated with dysregulation of the immune system, activation of immune cells, and massive release of cytokines, commonly known as the cytokine storm (CS). The clinical manifestations of SS depend on the initial site of infection. However, the classi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * a septic shock in the early, acute phase, * respiratory insufficiency required mechanical ventilation with PaO2/FiO2 \< 150, * bacterial infection, * procalcitonin higher than 5 ng/mL and interleukin 6 higher than 100 pg/mL, * no allergy to hops or their derivatives, * hemodyn…
Contacts

Wojciech Dabrowski, Prof

+48604241040

wojciech.dabrowski@umlub.pl

CONTACT

Wojciech Dabrowski

+48604241040

w.dabrowski5@yahoo.com

CONTACT